Merck sues to stop Medicare drug price negotiations; doctors delay lifesaving therapies due to cancer drug shortages; a federal appeals court will hear Affordable Care Act coverage prevention case.
Merck Sues US Government Over Medicare Drug Price Negotiations
On Tuesday, Merck & Co filed a lawsuit against the US government seeking to block a drug price negotiation program included in the Inflation Reduction Act, according to Reuters. The company argued that the program violates the Fifth and First Amendments of the US Constitution and marks the first challenge by a drugmaker to the law. Merck stated it plans to take this case all the way to the Supreme Court if necessary.
Cancer Drug Shortages Reach a New Record-High
A severe shortage of effective chemotherapy drugs is ultimately putting at risk the lives of patients with cancer, according to The Washington Post. The shortage, exacerbated by low profit margins on generic drugs and an overreliance on foreign manufacturing, is affecting a wide range of cancer treatments, including pediatric cases. Furthermore, delays in treatment caused by the shortage may have devastating consequences, with studies showing increased sickness or mortality rates for common cancers when treatment is delayed.
Appeals Court to Hear Texas Case Against ACA Provision Mandate
A federal appeals court is considering whether to continue the temporary pause of a Texas district court's ruling that invalidated an Affordable Care Act provision mandating insurers to cover preventive services for free, according to The Hill. The pause allows HHS to continue requiring insurance companies to cover preventive services such as HIV prevention drugs and cancer screenings without cost-sharing. The case was brought forward by conservative Texas employers and individuals, who believe the provision violates their religious beliefs.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Reducing Readmissions in the Safety Net Through AI and Automation
March 6th 2025Artificial intelligence (AI) and electronic health record–based automation tools helped a safety-net health system meet performance-based readmission metrics, thereby retaining critical funding while improving clinical and equity outcomes.
Read More
Facilitators of and Barriers to Medicaid Investment in Electronic Consultation Services
March 5th 2025In this qualitative investigation, leaders of Medicaid managed care plans were interviewed to identify facilitators of and barriers to electronic consultation for specialty care delivery.
Read More